by Esme Fowler-Mason | Apr 9, 2026 | Access to Care, NCD Partnerships, News
As a member of the UICC-led ATOM Coalition, NCDconnect has partnered with Bristol Myers Squibb (BMS) and Coalition partners to help implement BMS’ Innovative Medicines Access Program (IMAP). NCDconnect plays a critical role in this by designing country-specific...
by Esme Fowler-Mason | Nov 27, 2025 | Healthcare Systems, NCD Solutions, News
Noncommunicable diseases (NCDs) are on the rise across low- and middle-income countries (LMICs), adding pressure to already complex health supply chains. Ensuring consistent, affordable access to essential NCD medicines remains a critical, and often under-addressed,...
by Esme Fowler-Mason | Oct 23, 2025 | Access to Care, NCD Solutions, News
Rituximab, a life-saving monoclonal antibody used in the treatment of blood cancers, is now available as a biosimilar through NCDconnect, ensuring quality, affordability, and access to targeted cancer therapies across low- and middle-income countries (LMICs). Pharmacy...
by Esme Fowler-Mason | Jul 15, 2025 | Access to Care, NCD Solutions, News
The collaboration between IDA Foundation’s NCDconnect initiative and the Access to Oncology Medicines (ATOM) Coalition, led by the Union for International Cancer Control (UICC), is making significant strides toward improving access to cancer care in low- and...
by Esme Fowler-Mason | Jun 26, 2025 | Access to Care, NCD Partnerships, News
In many low- and middle-income countries (LMICs), a childhood cancer diagnosis often comes with limited access to timely treatment, essential medicines, and consistent care. That’s why earlier this year, NCDconnect—through IDA Foundation—joined the Access Cancer...
by Esme Fowler-Mason | May 15, 2025 | Healthcare Systems, NCD Policy, News
World Hypertension Day 2025 | Theme: “Measure Your Blood Pressure Accurately, Control It, Live Longer” High blood pressure (hypertension) remains one of the leading risk factors for cardiovascular disease and premature death worldwide. Yet in many low- and...
